US 12,310,992

Application 18/535,745 · Granted May 27, 2025

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

Estimated expiration

July 30, 2033

6y 253d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Jul 30, 2013
+ 20 years
Jul 30, 2033
PTA +0d
Jul 30, 2033
TD applied
Jul 30, 2033
Final
Jul 30, 2033

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
December 11, 2023
Earliest effective filing
July 30, 2013
Issue date
May 27, 2025
PTA
0 days
Base expiry (before PTA)
July 30, 2033

July 30, 2013 + 20 years = July 30, 2033

  • Divisional of application 17/072,430, filed Oct 16, 2020, issued as US 11,839,631
  • Continuation of application 16/002,250, filed Jun 7, 2018, issued as US 10,842,823
  • Divisional of application 14/418,557, filed Jan 30, 2015, issued as US 10,016,463
  • National stage entry of application PCTUS2013052700, filed Jul 30, 2013
  • National stage entry of application PCTUS2013052700, filed Jul 30, 2013
  • Divisional of application 14/418,557, filed Jan 30, 2015, issued as US 10,016,463
  • National stage entry of application PCTUS2013052700, filed Jul 30, 2013
  • Continuation of application 16/002,250, filed Jun 7, 2018, issued as US 10,842,823
  • Divisional of application 14/418,557, filed Jan 30, 2015, issued as US 10,016,463
  • National stage entry of application PCTUS2013052700, filed Jul 30, 2013
  • PRO61/678,208 — Provisional — not used for base term
  • PRO61/750,458 — Provisional — not used for base term
  • PRO61/678,208 — Provisional — not used for base term
  • PRO61/750,458 — Provisional — not used for base term
  • PRO61/678,208 — Provisional — not used for base term
  • PRO61/750,458 — Provisional — not used for base term
  • PRO61/678,208 — Provisional — not used for base term
  • PRO61/750,458 — Provisional — not used for base term
  • PRO61/678,208 — Provisional — not used for base term
  • PRO61/750,458 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to July 30, 2033

  • US 11,141,393· Application 16/137,629Capping patent

    Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

    Filing date
    Sep 21, 2018
    Earliest effective filing
    Jan 8, 2014
    Issue date
    Oct 12, 2021
    PTA
    +107 days
    Calculated expiration
    Apr 25, 2034

    Divisional of 14/149,929, filed Jan 8, 2014, issued as US 10,080,730

    Jan 8, 2014 + 20y + 107d PTA = Apr 25, 2034

  • US 10,016,463· Application 14/418,557Capping patent

    Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

    Filing date
    Jan 30, 2015
    Earliest effective filing
    Jul 30, 2013
    Issue date
    Jul 10, 2018
    PTA
    +93 days
    Calculated expiration
    Oct 31, 2033

    National stage entry of PCTUS2013052700, filed Jul 30, 2013

    Jul 30, 2013 + 20y + 93d PTA = Oct 31, 2033

  • US 12,310,992· Application 18/535,745(from application 18/535,745)Capping patent

    Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

    Filing date
    Dec 11, 2023
    Earliest effective filing
    Jul 30, 2013
    Issue date
    May 27, 2025
    PTA
    0 days
    Calculated expiration
    Jul 30, 2033

    Divisional of 17/072,430, filed Oct 16, 2020, issued as US 11,839,631

    Continuation of 16/002,250, filed Jun 7, 2018, issued as US 10,842,823

    Divisional of 14/418,557, filed Jan 30, 2015, issued as US 10,016,463

    National stage entry of PCTUS2013052700, filed Jul 30, 2013

    National stage entry of PCTUS2013052700, filed Jul 30, 2013

    Divisional of 14/418,557, filed Jan 30, 2015, issued as US 10,016,463

    National stage entry of PCTUS2013052700, filed Jul 30, 2013

    Continuation of 16/002,250, filed Jun 7, 2018, issued as US 10,842,823

    Divisional of 14/418,557, filed Jan 30, 2015, issued as US 10,016,463

    National stage entry of PCTUS2013052700, filed Jul 30, 2013

    Jul 30, 2013 + 20y = Jul 30, 2033

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 18/535,745 · US 12,310,992

PatentReply compiles the prosecution history behind US 12,310,992: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12310992

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.